Roche Confirms Pharma Appetite for Inflammatory Disease Treatments
Roche’s acquisition of the Irish biotech Inflazome is a vote of confidence for emerging inflammatory…
Roche’s acquisition of the Irish biotech Inflazome is a vote of confidence for emerging inflammatory…
Public and private organizations across Europe will pool their resources in an €80M project to…
Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to…
Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with…
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody…
Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000…
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies…
Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive…
Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a…
Now that we've got the bad news out of the way, we're here to spread…